Northern Trust Corp Grows Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Northern Trust Corp lifted its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 10.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 547,050 shares of the company’s stock after acquiring an additional 51,960 shares during the quarter. Northern Trust Corp owned 0.54% of Day One Biopharmaceuticals worth $6,931,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in Day One Biopharmaceuticals in the fourth quarter valued at approximately $866,000. R Squared Ltd purchased a new stake in shares of Day One Biopharmaceuticals in the 4th quarter valued at $31,000. China Universal Asset Management Co. Ltd. lifted its stake in Day One Biopharmaceuticals by 11.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company’s stock worth $271,000 after acquiring an additional 2,180 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in Day One Biopharmaceuticals by 16.7% during the 4th quarter. Handelsbanken Fonder AB now owns 31,500 shares of the company’s stock valued at $399,000 after acquiring an additional 4,500 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Day One Biopharmaceuticals by 43.4% during the 4th quarter. Bank of New York Mellon Corp now owns 244,829 shares of the company’s stock valued at $3,102,000 after acquiring an additional 74,091 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on DAWN. The Goldman Sachs Group cut their price target on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday, March 25th. JPMorgan Chase & Co. reduced their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. Wedbush reissued an “outperform” rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC cut their price objective on Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $30.57.

Day One Biopharmaceuticals Trading Up 3.7%

Shares of NASDAQ:DAWN opened at $6.48 on Tuesday. Day One Biopharmaceuticals, Inc. has a 52 week low of $6.08 and a 52 week high of $16.76. The company’s 50 day moving average is $7.40 and its two-hundred day moving average is $10.71. The company has a market cap of $656.83 million, a PE ratio of -6.29 and a beta of -1.24.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.11. The firm had revenue of $30.76 million for the quarter, compared to analyst estimates of $30.28 million. As a group, equities research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insider Transactions at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 4,552 shares of Day One Biopharmaceuticals stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $28,495.52. Following the sale, the general counsel now directly owns 47,136 shares in the company, valued at $295,071.36. This trade represents a 8.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Charles N. York II sold 4,282 shares of the business’s stock in a transaction on Friday, May 16th. The shares were sold at an average price of $6.26, for a total transaction of $26,805.32. Following the completion of the sale, the chief financial officer now directly owns 265,231 shares of the company’s stock, valued at approximately $1,660,346.06. This trade represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,725 shares of company stock valued at $167,299. 6.20% of the stock is currently owned by corporate insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.